Rewcastle, G.W., Denny, W.A., Bridges, A.J., Zhou, H., Cody, D.R., McMichael, A. and Fry, D.W. (1995) Tyrosine Kinase Inhibitors. Synthesis and Structure-Activity Relationships for 4-[(Phenylmethyl)amino] and 4-(Phenylamino) Quinazolines as Potent Adenosine 5’-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 38, 3482-3487.
http://dx.doi.org/10.1021/jm00018a008

has been cited by the following article:

• TITLE: In Silico Pharmacokinetics Studies for Quinazolines Proposed as EGFR Inhibitors

  AUTHORS: Gabriela Souza Fernandes, Michelle Bueno de Moura Pereira, Ana Cláudia Barbosa Marinho, Brisa Machado, Ana Carla Moreira, Matheus Puggina de Freitas, Karen Luise Lang, João Eustáquio Antunes

  KEYWORDS: Cancer Treatment, Quinazoline, Inhibitors, Rational Drug Design, Pharmacokinetics

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.5 No.4, December 25, 2015

  ABSTRACT: In silico pharmacokinetics studies can aid the search for molecules with potential ability to be drug candidates. In this paper, a number of quinazoline candidates for epidermal growth factor receptor inhibitors—EGFR, important targets for the treatment of cancer, are computationally analyzed. The literature described that 69 quinazoline molecules were synthesized and the respective half maximum inhibitory concentrations (IC50) were obtained. A bilinear parabolic model was built to investigate the druglikeness by correlating the corresponding lipophilicities, which can be represented by the ideal Log P , with the optimal biological activity in terms of pIC50 values. Structural characteristics leading to improved pharmacokinetics parameters were then analyzed. Compound 56 exhibited the lowest IC50 and, therefore, it had the highest ability to inhibit the EGFR. In the present work, the most potent inhibitor 56 is not calculated to be the most promising drug candidate, since it’s out of the parabolic model obtained due to a Log P above 5, which is not within the expected optimum range. Finally, this work is an example of computational prediction that an experimentally, highly active EGFR inhibitor can be unsuccessful as drug candidate because of pitfalls in pharmacokinetics parameters.